EHA2023 abstracts: What’s hot in MDS?

S165

Oral presentation

Continuous tranfusion independence with imetelstat in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3

Uwe Platzbecker

S169

Oral presentation

Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency

Nicolas Chapuis

P492

Poster presentation

Safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia

Kristin Koenig

P689

Poster presentation

Classification of MDS and AML based solely on genetics omitting blast counting – a way to resolve the discrepancies between classifications according to WHO and ICC?

Claudia Haferlach

P724

Poster presentation

Updated substudy results for ivosidenib in IDH1-mutant relapsed/refractory myelodysplastic syndrome

Courtney DiNardo

P732

Poster presentation

Analysis of patient-reported fatigue in IMERGE Ph3 trial of imetelstat vs placebo in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes R/R to erythropoiesis stimulating agents

Mikkael Sekeres

P733

Poster presentation

Treatment patterns and outcomes among patients with lower-risk myelodysplastic syndromes receiving luspatercept in routine clinical practice in the United States

Sudipto Mukherjee

P736

Poster presentation

Analysis of response rates and outcomes in erythroid-predominant myelodysplastic syndromes (MDS) treated with venetoclax-based regimens

Alexandre Bazinet

P1270

Poster presentation

Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: results of a randomized clinical trial comparing 2 fractionation schedules

Uday R. Popat

P1290

Poster presentation

Upfront allogeneic hematopoietic stem cell transplantation can provide survival benefit versus hypomethylating agent in myelodysplastic syndrome with increased blasts I (MDS-IBI)

Runzhi Ma

S102

Plenary session

Luspatercept versus epoetin alfa for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions: data from the phase 3 commands study

Matteo Giovanni Della Porta

S164

Oral presentation

Disease modifying activity of imetelstat in patients with heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3

Valeria Santini

S172

Oral presentation

Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

Alex Bataller

S173

Oral presentation

Retrospective study of lenalidomide discontinuation in patients with myelodysplastic syndrome harboring del(5q). A harmony alliance study

Elena Crisà

S174

Oral presentation

Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT study group

Lisa Pleyer

s265

SWG session

Myelodysplastic syndromes: myelodysplastic neoplasms given the new WHO classification

Chair: Uwe Platzbecker